BioSpace News Archive

Drug Development

In Expected Decision, FDA Rejects Lilly’s Sintilimab in NSCLC

The U.S. Food and Drug Administration rejected Eli Lilly’s Biologics License Application, issuing a Complete Response Letter for the company’s PD-1 checkpoint inhibitor sintilimab.

March 24, 2022
·
3 min read
·
Mark Terry
Celsius Nets $83M to Bring Precision IBD Treatment to Trial

Celsius Therapeutics raised $83 million in funding, paving the way for several ambitious projects announced in its recently released key initiatives for 2022.

March 24, 2022
·
2 min read
·
Hannah Chudleigh
An Unlikely Pair: New Pancreatic Cancer Vaccine Utilizes Immunity from Tetanus

Researchers at Albert Einstein College of Medicine have cleverly developed a vaccine for pancreatic cancer by using the adaptive immunity already present in nearly all of the global population.

March 24, 2022
·
2 min read
·
Jazmine Colatriano
Deals

Ligand’s New Antibody Business Prepares to Hit the Nasdaq

Ligand will spin off its antibody discovery business into a new entity known as OmniAb, Inc., which will then merge with Avista Capital Partners and head to The Nasdaq Stock Market.

March 24, 2022
·
2 min read
·
Alex Keown
Drug Development

FDA Approves First Targeted Radioligand Therapy for Advanced Prostate Cancer

The FDA approved Pluvicto (targeted radioligand therapy) for use in adults with PSMA-positive mCRPC that has already metastasized to other body parts.

March 24, 2022
·
2 min read
·
Vanessa Doctor, RN
Drug Development

Research Roundup: Halting Memory Loss in Alzheimer’s, COVID-19 and Diabetes

A recent study in mice was able to halt memory decay in a model of Alzheimer’s disease. Another study found that even mild infection increased the risk of new-onset type 2 diabetes, although the risk increased with the severity of COVID-19.

March 24, 2022
·
5 min read
·
Mark Terry
Business

BiondVax Inks Deal for NanoAbs, Totus Doubles Down on AI

Terms of the deal provide BiondVax with an option for a worldwide license to develop and commercialize the NanoAbs, which are also known as VHH-antibodies or nanobodies.

March 24, 2022
·
3 min read
·
Alex Keown
Business

Orion Honing in on Cancer and Pain in Shift Away From Neuro

Orion Corporation announced its plans to shift focus to new proprietary drugs in oncology and pain, expecting to cut 37 jobs.

March 24, 2022
·
3 min read
·
Mark Terry
FDA

Pfizer Notches Breakthrough Status in Race to an RSV Vaccine

Pfizer has announced it received Breakthrough Therapy Designation from the FDA for its vaccine candidate intended to prevent infections caused by the respiratory syncytial virus (RSV).

March 24, 2022
·
3 min read
·
Hayley Shasteen
Drug Development

Jazz Doses First Patient in Broad Trial for Promising Cancer Drug

The Phase II trial is evaluating zepzelca as a monotherapy in patients with urothelial carcinoma, large cell neuroendocrine carcinoma of the lung and HRD tumors.

March 24, 2022
·
3 min read
·
Hayley Shasteen